7/105 sources · 3 publishersUpdated Nov 18, 15:01 UTC
Stifel upgrades Tandem Diabetes to Buy and raises price target to $26
Stifel Securities lifted its rating on Tandem Diabetes Care to Buy from Hold and increased its price target to $26, up from $22. The firm noted improving margins, a stronger product pipeline and recent FDA clearance for the Tandem Mobi tubeless insulin delivery system. The stock was trading around $17.06 at the time of the upgrade.
Why it matters
Stifel’s upgrade and higher price target suggest roughly 50% upside, which could attract buying interest and lift the share price. The analyst’s view is reflected in the pre‑market rally of about 5‑6% following the note.
Key facts
- 1Stifel upgraded Tandem Diabetes Care to Buy from Hold. investing.com
- 2Stifel raised its price target to $26, up from $22. investing.com
- 3The stock was trading at $17.06 when the upgrade was announced. investing.com
- 4Tandem Diabetes received 510(k) clearance from the FDA for its Tandem Mobi tubeless insulin delivery system. investing.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.